JAK3 and psoriasis: In CD18-deficient mice with a psoriasis-like phenotype, the active metabolite of R348, R333 (Rigel Pharmaceuticals, San Francisco CA, USA), inhibits Jak3- and Syk-dependent pathways and reduces cellular Th1 and Th2 immune responses (131).